The diagnostics and life sciences tools sector is attracting continued investor interest across both private equity and large ...

The National Medical Products Administration (NMPA) has cleared Yochanra (tinengotinib) for adult patients with unresectable ...

At its third attempt, Replimune has finally won FDA approval for its advanced melanoma treatment RP1, giving the company its ...

Takeda's orexin agonist Orzeyful has been approved in the US to treat narcolepsy type 1 (NT1) in adults, becoming the first ...

Koray Kavukcuoglu, DeepMind's chief technology officer and Google's chief AI architect, is taking on the operational ...

Under the terms of the deal, ‌Lantheus' shareholders will get $102.50 per share in cash when the deal closes, along with the ...

Sentiment towards Novo Nordisk was also hit by the acknowledgement that it has decided to abandon the development of ...

Tarsus is paying $450 million upfront for Alkeus – made up of $270 million in cash and $180 million in stock – with another ...

For an emerging biopharma company developing an innovative therapy for a rare condition, 2026 presents a dilemma that may ...

A Netherlands-based compounding pharmacy has been ordered to stop distributing a compounded nasal spray formulation of Novo Nordisk's GLP-1 agonist semaglutide in a test of the country's pharmacy ...

For decades, direct-to-consumer (DTC) advertising has been a defining feature of the US healthcare system. Across the nation, ...

Moderna has started first-in-human testing of its mRNA vaccine against Bundibugyo Ebola virus (BDBV), now causing the ...